Guggenheim initiated coverage on Absci Corporation with a new price target
$ABSI
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Guggenheim initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $10.00